JGC
SLDB icon

J. Goldman & Co’s Solid Biosciences SLDB Stock Holding History

J. Goldman & Co’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.42M Sell
242,164
-42,303
-15% -$321K 0.06% 312
2026
Q1 		$2.05M Buy
+284,467
New +$1.83M 0.06% 314
2024
Q4 		– Sell
-94,500
Closed -$659K – 612
2024
Q3 		$659K Buy
+94,500
New +$766K 0.02% 327

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

J. Goldman & Co's SLDB Position: Q2 2026 in Review

J. Goldman & Co reduced its Solid Biosciences (SLDB) stake by 15% in Q2 2026, selling an estimated $321K and leaving 242,164 shares worth $2.42M. The position accounts for 0.06% of the portfolio, ranked #312.

J. Goldman & Co first reported a position in SLDB in Q3 2024 and has held it in 3 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • J. Goldman & Co held 242,164 shares of Solid Biosciences worth $2.42M as of Q2 2026.
  • J. Goldman & Co sold 42,303 Solid Biosciences shares in Q2 2026, an estimated $321K.
  • Solid Biosciences made up 0.06% of J. Goldman & Co's portfolio in Q2 2026, its #312 holding.
  • J. Goldman & Co first reported a position in Solid Biosciences in Q3 2024 and has held it in 3 quarters since.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.